Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.
作者信息
Hughes Carly M, Gregory Gareth P, Pierce Anna B, Druce Julian D, Catton Mike, Chong Brian, Sherry Norelle L, Graham Maryza, Chen Melissa, Salvaris Ross, Eise Nicole, Lee Jean Y H, McQuilten Zoe, Crouch Simon, Looker Clare, Korman Tony M, Stuart Rhonda L
机构信息
Monash Infectious Diseases, Monash Health, Clayton, Victoria, Australia.
Department of Microbiology, Monash Pathology, Monash Health, Clayton, Victoria, Australia.
出版信息
Infect Control Hosp Epidemiol. 2022 Jun;43(6):820-822. doi: 10.1017/ice.2021.120. Epub 2021 Mar 19.
Abstract
摘要
相似文献
1
Clinical illness with viable severe acute respiratory coronavirus virus 2 (SARS-CoV-2) virus presenting 72 days after infection in an immunocompromised patient.一名免疫功能低下患者在感染严重急性呼吸综合征冠状病毒2（SARS-CoV-2）病毒72天后出现伴有活病毒的临床疾病。
Infect Control Hosp Epidemiol. 2022 Jun;43(6):820-822. doi: 10.1017/ice.2021.120. Epub 2021 Mar 19.
2
Genomic Evolution of SARS-CoV-2 Virus in Immunocompromised Patient, Ireland.爱尔兰免疫功能低下患者体内 SARS-CoV-2 病毒的基因组进化。
Emerg Infect Dis. 2021 Sep;27(9):2499-2501. doi: 10.3201/eid2709.211159. Epub 2021 Jun 23.
3
COVID-19 in an immunocompromised host: persistent shedding of viable SARS-CoV-2 and emergence of multiple mutations: a case report.免疫功能低下宿主中的 COVID-19：活 SARS-CoV-2 的持续排出和多种突变的出现：一例报告。
Int J Infect Dis. 2022 Jan;114:178-182. doi: 10.1016/j.ijid.2021.10.045. Epub 2021 Oct 29.
4
Prolonged viral shedding of SARS-CoV-2 in two immunocompromised patients, a case report.两名免疫功能低下患者的 SARS-CoV-2 病毒持续排出：病例报告
BMC Infect Dis. 2021 Aug 3;21(1):743. doi: 10.1186/s12879-021-06429-5.
5
Absence of long-range severe acute respiratory coronavirus virus 2 (SARS-CoV-2) transmission from a highly infectious patient with undiagnosed coronavirus disease 2019 (COVID-19) in a positive-pressure room.在一间正压病房中，一名未被诊断出患有2019冠状病毒病（COVID-19）的高传染性患者未出现严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的远距离传播。
Infect Control Hosp Epidemiol. 2022 Jan;43(1):108-109. doi: 10.1017/ice.2021.327. Epub 2021 Jul 21.
6
COVID-19 in Elderly, Immunocompromised or Diabetic Patients-From Immune Monitoring to Clinical Management in the Hospital.COVID-19 与老年、免疫功能低下或糖尿病患者——从免疫监测到医院内的临床管理。
Viruses. 2022 Apr 1;14(4):746. doi: 10.3390/v14040746.
7
Yearlong COVID-19 Infection Reveals Within-Host Evolution of SARS-CoV-2 in a Patient With B-Cell Depletion.长达一年的 COVID-19 感染揭示了 B 细胞耗竭患者体内 SARS-CoV-2 的宿主内进化。
J Infect Dis. 2022 Apr 1;225(7):1118-1123. doi: 10.1093/infdis/jiab622.
8
Chronic Asymptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in the Immunocompromised Patient: New Challenges and Urgent Needs.免疫功能低下患者的慢性无症状严重急性呼吸综合征冠状病毒2（SARS-CoV-2）感染：新挑战与迫切需求
Clin Infect Dis. 2022 Feb 11;74(3):553. doi: 10.1093/cid/ciab538.
9
Immunocompromised Seroprevalence and Course of Illness of SARS-CoV-2 in One Pediatric Quaternary Care Center.免疫功能低下患者血清 SARS-CoV-2 阳性率和疾病进程：一家儿科四级保健中心的研究
J Pediatric Infect Dis Soc. 2021 Apr 30;10(4):426-431. doi: 10.1093/jpids/piaa123.
10
SARS-CoV-2 infection in immunocompromised patients: humoral versus cell-mediated immunity.SARS-CoV-2 感染免疫功能低下患者：体液免疫与细胞免疫。
J Immunother Cancer. 2020 Jul;8(2). doi: 10.1136/jitc-2020-000862.
引用本文的文献
1
COVID-19 outcome is not affected by anti-CD20 or high-titer convalescent plasma in immunosuppressed patients.COVID-19 结局不受免疫抑制患者抗 CD20 或高滴度恢复期血浆的影响。
Sci Rep. 2023 Dec 1;13(1):21249. doi: 10.1038/s41598-023-48145-x.
2
COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis.COVID-19 恢复期血浆治疗免疫功能低下患者：系统评价和荟萃分析。
JAMA Netw Open. 2023 Jan 3;6(1):e2250647. doi: 10.1001/jamanetworkopen.2022.50647.
3
Use of convalescent plasma in COVID-19 patients with immunosuppression.COVID-19 免疫抑制患者使用恢复期血浆。
Transfusion. 2021 Aug;61(8):2503-2511. doi: 10.1111/trf.16525. Epub 2021 Jun 1.
Zotero 插件